Maywood I is a dysfunctional plasminogen. It is described in a patient (W. Y) with a reduced plasma functional activity and with a low normal antigen level. Plasminogen was isolated from the patients plasma by affinity chromatography with L-lysine-substituted Sepharose. The protein yield was 86 mg/1, which was 88% of the plasma Plg antigen level; the specific activity was 24.4 IU/mg protein compared to 28.5 IU/mg protein for the native molecule. The protein was the Glu-form determined by SDS-PAGE and by isoelectric focusing. Six major isoelectric forms were found with isoelectric points between pH's 6.40 and 5.45. Titration of the equimolar plasminogen.streptokinase complex with p-nitrophenyl-p-guanidinobenzoate gave 85% active-sites indicating a homogenous population of molecules; therefore, the propositus is a homozygote. Four different plasminogen activators: a) streptokinase, b) urokinase c) the plasmin-derived light (B) chain-streptokinase complex, and d) tissue plasminogen activator (with soluble fibrin/CNBr-fibrinogen fragments) generated little plasmin from the variant plasminogen (4.5 to 45 nM), 5% or less than that generated from normal plasminogen. At 45 nM plasminogen, the molar ratio of plasminogen : activator was 3.0 for streptokinase, 3.9 for urokinase, 7.1 for the light (B) chain-streptokinase complex, and 155 for tissue plasminogen activator. In the equimolar variant plasminogen.streptokinase complex, the active-site was slowly developed, to a maximum of 85% in 40 min; in the normal complex, 100% active-sites were developed in 15 min. The variant plasminogen forms two equimolar complexes with streptokinase (I and II), with different mobilities in PAGE, in about equal amounts. About 10% of complex I (abnormal), with a slower mobility than complex II (normal), converts to plasmin.streptokinase in 60 min, whereas about 40% of complex II converts to plasmin.streptokinase in 60 min. A kinetic defect was also found with this variant plasminogen. It showed substantially lowered kinetics of activation second-order rate constants with both streptokinase and urokinase, primarily due to lower catalytic rate constants, and with streptokinase, a higher Michaelis constant. Crossed-immunoelectrophoresis, and preparative isoelectric focusing isoelectric points did not show a charge mutation. Maywood I may be classified as a dysplasminogenemia with active center and kinetic defects, Type 1c.
References
1
Aoki N.
Genetic abnormalities of the fibrinolytic system. Sem Thromb Haemostas 1984; 10: 42-50
4
Lijnen HR,
Collen D.
Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis. Fibrinolysis 1989; 3: 67-77
6
Petersen TE,
Martzen MR,
Ichinose A,
Davie EW.
Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 1990; 265: 6104-11
7
Aoki N,
Moroi M,
Sakata Y,
Yoshida N,
Matsuda M.
Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest 1978; 61: 1186-95
9
Miyata T,
Iwanaga S,
Sakata Y,
Aoki N.
Plasminogen Tochigi: Inactive plasmin resulting from replacement of alanine-600 by threonine in the active site. Proc Natl Acad Sci USA 1982; 79: 6132-6
10
Miyata T,
Iwanaga S,
Sakata Y,
Aoki N,
Takamatsu J,
Kamiya T.
Plasminogens Tochigi II and Nagoya: Two additional molecular defects with Ala-600 to Thr replacement found in plasmin light chain variants. J Biochem (Jpn) 1984; 96: 277-87
12
Godwin J,
Goodwin M,
Brown A,
Foy B,
Boreisha I,
Robbins KC.
Successful cardiac surgery in a patient with an abnormal plasminogen, Maywood I, and recurrent thrombosis. Blood 70 Suppl 1 373 (Abstract 1348)
14
Wohl RC,
Summaria L,
Robbins KC.
Physiological activation of the human fibrinolytic system. Isolation and characterization of human plasminogen variants. Chicago I and Chicago II. J Biol Chem 1979; 254: 9063-9
15
Wohl RC,
Summaria L,
Robbins KC.
Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37° C. J Biol Chem 1980; 255: 2005-13
17
Scharrer IM,
Wohl RC,
Hach V,
Sinio L,
Boreisha I,
Robbins KC.
Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis. Thromb Haemostas 1986; 55: 396-401
19
Robbins KC,
Summaria L,
Elwyn D,
Barlow GH.
Further studies of the purification and characterization of human plasminogen and plasmin. J Biol Chem 1965; 240: 541-50
23
Lee PP,
Wohl RC,
Boreisha IG,
Robbins KC.
Kinetic analysis of covalent hybrid plasminogen activators: Effect of CNBr-degraded fibrinogen on kinetic parameters of Glu1-plasminogen activation. Biochemistry 1988; 27: 7506-13
24
Becker W,
Rapp W,
Schwick HG,
Storiko K.
Methoden zur quantitativen Bestimmung von Plasmaproteinen durch Immunprôzipitation. Z Klin Chem Klin Biochem 1968; 3: 113-22
25
Friberger P,
Knos M,
Gustavsson S,
Aurell L,
Claeson G.
Methods for determination of plasmin, antiplasmin, and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-45
26
Summaria L,
Arzadon L,
Bernabe P,
Robbins KC,
Barlow GH.
Characterization of the NH2-terminal glutamic acid and NH2-terminal lysine forms of human plasminogen isolated by affinity chromatography and isoelectric focusing methods. J Biol Chem 1973; 248: 2984-91
